Pembrolizumab
RU021502I
Phase 2 mab active
Quick answer
Pembrolizumab for Metastatic Small Intestinal Adenocarcinoma is a Phase 2 program (mab) at United Therapeutics Europe Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- United Therapeutics Europe Ltd
- Indication
- Metastatic Small Intestinal Adenocarcinoma
- Phase
- Phase 2
- Modality
- mab
- Status
- active